The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study

Table 2 Association of survival after sunitinib therapy and the best objective response on target lesions

Best objective response on target lesions	Progression-free survival^†			Overall survival^†
Best objective response on target lesions	Median survial (months)	1-year (%)	3-years (%)	Median survial (months)	1-year (%)	3-years (%)
All cases	8.9	35	15	23.5	81	35
CR/PR	15.0	50	40	59.7	90	68
SD	9.2	41	23	24.2	81	38
PD	6.8	27	17	17.1	63	0
NE	2.2	10	0	18.1	60	10

IQR interquaterile range; CR complete response; PR pertial response; SD stable disease; PD progressive disease; NE not evaluated
^†Estimated with Kaplan–Meier method

ISSN: 1756-0500